BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freedman N, Sandström M, Kuten J, Shtraus N, Ospovat I, Schlocker A, Even-Sapir E. Personalized radiation dosimetry for PRRT-how many scans are really required? EJNMMI Phys 2020;7:26. [PMID: 32394075 DOI: 10.1186/s40658-020-00293-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Piwowarska-bilska H, Kurkowska S, Birkenfeld B. Individualization of Radionuclide Therapies: Challenges and Prospects. Cancers 2022;14:3418. [DOI: 10.3390/cancers14143418] [Reference Citation Analysis]
2 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
3 Kennedy J, Chicheportiche A, Keidar Z. Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy. Semin Nucl Med 2021:S0001-2998(21)00091-X. [PMID: 34911637 DOI: 10.1053/j.semnuclmed.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Carter LM, Ocampo Ramos JC, Kesner AL. Personalized dosimetry of177Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomed Phys Eng Express 2021;7. [PMID: 34271565 DOI: 10.1088/2057-1976/ac1550] [Reference Citation Analysis]
5 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
6 Monserrat Fuertes T, González García FM, Peinado Montes MÁ, Domínguez Grande ML, Martín Fernández N, Gómez de Iturriaga Piña A, Mínguez Gabiña P. Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:167-78. [PMID: 33811003 DOI: 10.1016/j.remn.2021.02.006] [Reference Citation Analysis]
7 Tano H, Oroujeni M, Vorobyeva A, Westerlund K, Liu Y, Xu T, Vasconcelos D, Orlova A, Karlström AE, Tolmachev V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. Cancers (Basel) 2021;13:500. [PMID: 33525578 DOI: 10.3390/cancers13030500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, Versari A, Iori M, Grassi E. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys 2020;7:63. [PMID: 33044651 DOI: 10.1186/s40658-020-00328-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]